KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Notes Payables (2016 - 2024)

Historic Notes Payables for Emergent BioSolutions (EBS) over the last 8 years, with Q3 2024 value amounting to $800000.0.

  • Emergent BioSolutions' Notes Payables fell 9980.66% to $800000.0 in Q3 2024 from the same period last year, while for Sep 2024 it was $800000.0, marking a year-over-year decrease of 9980.66%. This contributed to the annual value of $413.7 million for FY2023, which is 5678.47% down from last year.
  • Per Emergent BioSolutions' latest filing, its Notes Payables stood at $800000.0 for Q3 2024, which was down 9980.66% from $415.2 million recorded in Q2 2024.
  • Emergent BioSolutions' Notes Payables' 5-year high stood at $957.3 million during Q4 2022, with a 5-year trough of $800000.0 in Q3 2024.
  • Moreover, its 5-year median value for Notes Payables was $31.6 million (2021), whereas its average is $231.0 million.
  • As far as peak fluctuations go, Emergent BioSolutions' Notes Payables surged by 292943.04% in 2022, and later crashed by 9980.66% in 2024.
  • Quarter analysis of 5 years shows Emergent BioSolutions' Notes Payables stood at $33.8 million in 2020, then fell by 6.51% to $31.6 million in 2021, then soared by 2929.43% to $957.3 million in 2022, then plummeted by 56.78% to $413.7 million in 2023, then tumbled by 99.81% to $800000.0 in 2024.
  • Its last three reported values are $800000.0 in Q3 2024, $415.2 million for Q2 2024, and $459.2 million during Q1 2024.